Addressing Drug Resistance in the Hepatitis B Virus: New Developments and Perspectives

Du Kang^*
*Correspondence: Du Kang, Department of Life Science, Jilin Agricultural University, Changchun, China, Email:

Introduction

Hepatitis B virus remains a significant global health threat, infecting an estimated 290 million people worldwide and causing acute and chronic liver diseases, including cirrhosis and hepatocellular carcinoma. The advent of antiviral therapies has transformed the management of chronic HBV infections, significantly reducing liver-related morbidity and mortality. However, the emergence of drug resistance remains a major challenge in the effective treatment of HBV, especially in individuals who are on long-term antiviral therapy. Drug resistance in HBV complicates treatment regimens, leading to suboptimal outcomes, viral rebound, and increased risk of liver damage. In recent years, substantial progress has been made in understanding the mechanisms of HBV drug resistance, developing newer antiviral agents with higher barriers to resistance, and exploring potential strategies to address this growing problem. This article delves into the latest developments in HBV drug resistance, the underlying mechanisms, and new perspectives on overcoming this challenge [1-3].

Description

For instance, combining a analogue with pegylated interferon could enhance the chances of sustained virologic response and improve the likelihood of achieving long-term suppression of the virus. Combining agents with different mechanisms of action also reduces the chances of cross-resistance. Immune Modulators and Immunotherapies: Another promising approach to overcoming drug resistance is the use of immune modulators. Unlike conventional antiviral drugs, which directly target viral replication, immune modulators aim to strengthen the host's immune response. Agents such as interferons, immune checkpoint inhibitors, and T-cell-based therapies are under investigation for their ability to induce an effective immune response against HBV. Additionally, therapeutic vaccines that stimulate the immune system to recognize and attack HBV-infected cells are also in the pipeline. These vaccines could provide a more durable and long-term solution compared to traditional antiviral drugs. Gene Editing Technologies: Gene-editing technologies, have opened up new possibilities for curing chronic HBV infections. By targeting the HBV DNA integrated into the host genome or by editing out the viral genome, CRISPR technology offers the potential to eliminate the virus completely. While still in early stages, these approaches are being explored in preclinical studies and may offer a future cure for HBV. Long-Acting Antiviral Agents: The development of long-acting antiviral therapies is another promising area. Injectable formulations of antivirals, which can be administered less frequently than daily oral pills, are being investigated for both HIV and HBV. These long-acting therapies could improve adherence and reduce the risk of resistance by ensuring consistent viral suppression [4,5].

Conclusion

Drug resistance in hepatitis B virus remains a significant challenge in the management of chronic HBV infections. The development of resistance mutations to existing antiviral therapies can lead to treatment failure and complications, particularly in patients with long-term infections. However, recent developments in antiviral drug classes, immune modulators, combination therapies, and gene editing technologies provide hope for overcoming these challenges. As research continues to evolve, the future of HBV treatment may shift towards personalized, long-term, and potentially curative therapies that address drug resistance and improve patient outcomes. Furthermore, the ultimate goal in HBV treatment is to achieve a functional cure, defined as long-term control of the virus without the need for continuous therapy. While this remains a distant goal for most patients, ongoing research into the combination of antiviral drugs with immune therapies, as well as gene-editing approaches, holds promise for a future where HBV can be eradicated or effectively controlled without lifelong treatment.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Skrzat-Klapaczyńska, Agata, Marcin Paciorek, Andrzej Horban and Justyna D. Kowalska. "Factors associated with the risk of upper respiratory tract bacterial infections among HIV-positive patients." Plos One 17 (2022): e0270770.

   Google Scholar, Crossref, Indexed at

2. Weber, M. S. R., J. J. Duran Ramirez, M. Hentzien and M. Cavassini, et al. "Time Trends in Causes of Death in People with HIV: Insights from the Swiss HIV Cohort Study." Clin Infect Dis (2024).

   Google Scholar, Crossref, Indexed at

3. Skrzat-Klapaczyńska, Agata, Justyna D. Kowalska, Bartłomiej Matłosz and Agnieszka Bednarska, et al. "Non-AIDS-defining bacterial infections in patients with HIV infection." Przegl Epidemiol 73 (2019).

   Google Scholar, Crossref, Indexed at

4. Johnson, Tanner M., Donald G. Klepser, Sara H. Bares and Kimberly K. Scarsi. "Predictors of vaccination rates in people living with HIV followed at a specialty care clinic." Hum Vaccin Immunother 17 (2021): 791-796.

   Google Scholar, Crossref, Indexed at

5. Jilich, David, Agata Skrzat‐Klapaczyńska, Lukas Fleischhans and Dominik Bursa, et al. "National strategies for vaccination against COVID‐19 in people living with HIV in Central and Eastern European region." HIV Med 23 (2022): 546-552.

   Google Scholar, Crossref, Indexed at